Treatment of Fuchs' Endothelial Corneal Dystrophy - Patent EP3592365A1
Summary
The European Patent Office granted patent EP3592365A1 to the University of Texas System and University of Massachusetts Medical School on April 8, 2026, covering oligonucleotide compositions for treating Fuchs' Endothelial Corneal Dystrophy. The patent is designated for all European patent states including DE, FR, GB, IT, NL, ES, and 26 others.
What changed
The European Patent Office published patent EP3592365A1 covering oligonucleotide compositions for treating Fuchs' Endothelial Corneal Dystrophy. The patent names the University of Texas System and University of Massachusetts Medical School as applicants, with designated states covering all major European jurisdictions.
For biotechnology and pharmaceutical companies, this patent establishes enforceable intellectual property rights that may affect research and development strategies in corneal disease treatment. Interested parties should monitor for potential licensing opportunities and assess freedom-to-operate implications.
What to do next
- Monitor for patent enforcement and commercialization developments
- Evaluate potential licensing opportunities with patent holders
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TREATMENT OF FUCHS' ENDOTHELIAL CORNEAL DYSTROPHY
Publication EP3592365A1 Kind: A1 Apr 08, 2026
Applicants
The Board Of Regents Of The University
Of Texas System, University of Massachusetts Medical School
Inventors
MOOTHA, Venkateswara, V., COREY, David, R., HU, Jiaxin, WATTS, Jonathan, K.
IPC Classifications
C12N 15/113 20100101AFI20201207BHEP C12N 15/11 20060101ALI20201207BHEP A61K 31/712 20060101ALI20201207BHEP A61K 31/713 20060101ALI20201207BHEP A61P 27/02 20060101ALN20201207BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.